JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prostate cancer screening: Is it time for a new approach? A review article

  • 0University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research +

|

August 29, 2024

|

August 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Prostate cancer screening using PSA and DRE improves survival but has low accuracy for clinically significant prostate cancer (CSPC). Research is ongoing to enhance early detection and reduce unnecessary procedures.

Area Of Science

  • Urology
  • Oncology
  • Medical Diagnostics

Background

  • Prostate cancer screening faces challenges due to the limitations of traditional methods like prostate-specific antigen (PSA) and digital rectal exam (DRE).
  • These methods have a low positive predictive value for clinically significant prostate cancer (CSPC), resulting in unnecessary biopsies and potential complications.

Purpose Of The Study

  • To address the limitations of current prostate cancer screening tools.
  • To explore novel approaches and secondary analyses of existing trials to improve the detection of clinically significant prostate cancer.

Main Methods

  • Secondary analysis of data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • Investigating the association between Prostate-Specific Antigen (PSA) levels and the presence of clinically significant prostate cancer (CSPC).
  • Evaluating novel diagnostic tools such as IP1-PROSTAGRAM Tri.

Main Results

  • Traditional screening tests (PSA, DRE) show a significant impact on prostate-cancer-specific mortality.
  • However, these tests exhibit a poor positive predictive value for identifying clinically significant prostate cancer (CSPC).
  • Ongoing research aims to refine screening accuracy and minimize false positives.

Conclusions

  • Optimizing prostate cancer screening remains a critical clinical challenge.
  • Further research and analysis of trials like PLCO are essential for improving the specificity of screening tests.
  • Novel diagnostic strategies are needed to reduce unnecessary biopsies and associated complications.

Keywords: